In total, 20 primary AML bone-marrow samples were collected and used for the isolation of primary CD34+ leukemia blasts, where CD34+ is a well-characterized biomarker of leukeima stem and progenitor cells. This evidence concerns the gene CD34 and acute myeloid leukemia.